Report Ocean has published a new report on the Pruritus Therapeutics Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers a ...

Eun Lee, MD Itching (also known as pruritus) is a common symptom of diabetes, a chronic condition characterized by high blood ...

Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...

Let’s dissect seven symptoms that Black people from all walks of life should recognize, and what they can do to address them.

Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted ...

In the three aforementioned studies of epidural delivery of naloxone in combination with an opioid (fentanyl or morphine), the frequency of pruritus was decreased, with no reversal of analgesia noted.

Published reports on placebo-controlled clinical trials and other studies investigating the use of pure opioid antagonists for the prevention and treatment of opioid-induced pruritus (OIP ...

BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ('Tharimmune' or the 'Company'), a clinical-stage biotechnology ...

Kayfanda® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for ...

Shares of Tharimmune Inc. shot up more than 100% in early trading Oct. 30 as the firm disclosed regulatory backing to launch a phase II trial this quarter testing TH-104, a transdermal buccal film ...

The unique feline dermatological cases veterinary professionals can see at the clinic, plus how to approach them ...

"The recent regulatory feedback from the EMA builds on the previous positive interactions with the FDA while providing a roadmap for TH104 for chronic pruritus in PBC, which continues to be a ...